Regulatory & Legal

A top shareholder claims Japan's leading toilet maker is a key AI supplier, revealing a $3.6B value gap and demanding a radical corporate transformation.

A major update to the Kosmos platform brings cart-grade OB/GYN and vascular tools to a portable device, reshaping diagnostics from the ER to rural clinics.

A new report shows most audit leaders see AI fraud as a top risk, yet less than 40% feel equipped to fight it, exposing a critical corporate vulnerability.

In a landmark $9.9 billion all-cash deal, Danaher will acquire Masimo, aiming to dominate the patient monitoring market from hospital to home.

Acorns adds free tax filing, but the real play is its push to automatically invest your refund, a move aimed at reshaping personal finance habits.

A partnership between NSA Labs and Proscia is slashing study times for brain research, showing how digital platforms are key to finding new therapies faster.

A major patent deal shields Esperion's flagship drugs from generics, securing future revenue but delaying cheaper options for millions of patients.

With a new rotator cuff device and enhanced meniscal repair system, Arcuro Medical is challenging orthopedic giants with its innovative all-suture technology.

With its new SOC 2 Type 2 certification, Tech Foundry aims to set a new standard for secure, high-touch software development for SaaS enterprises.

ASCU pays millions to end its partnership with a Rio Tinto venture, betting it can develop the massive Cactus copper project in Arizona all on its own.

Cyrano Therapeutics' CYR-064 shows promise in a Phase 2 study, potentially becoming the first approved drug for persistent post-viral smell loss.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

A new report reveals chronic underfunding and human error leave U.S. public services dangerously exposed to relentless ransomware and phishing attacks.

A new supply agreement for the rare isotope Actinium-225 between NorthStar and BIOEMTECH promises to break a critical bottleneck in radiopharmaceutical R&D.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

A new series from A3 and BBC StoryWorks moves beyond efficiency to show how automation is augmenting human lives in healthcare, education, and more.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

Lufax names Xiang Ji as its new CEO amid major financial struggles. The move signals a tighter grip from controlling shareholder Ping An Group.

A new program in Michigan uses AI to analyze existing CT scans, detecting silent heart risks and connecting patients to care before symptoms even appear.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.